AOD-9604 & CJC-1295 & Ipamorelin vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604 & CJC-1295 & Ipamorelin
A targeted fat loss stack combining AOD-9604 (the fat-burning fragment of HGH) with CJC-1295 and Ipamorelin for comprehensive body recomposition. This blend addresses fat loss directly while supporting lean mass through GH optimization.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 & CJC-1295 & Ipamorelin | Cagrilintide |
|---|---|---|
| Mechanism | AOD-9604 stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or blood glucose. CJC-1295 and Ipamorelin provide sustained and pulsatile GH release to support metabolism and lean tissue. The combination targets fat loss through multiple mechanisms while preserving muscle. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Typical protocol: AOD-9604 200-400mcg, CJC-1295 100-200mcg, Ipamorelin 100-200mcg daily. Usually administered in the morning fasted or before exercise. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Subcutaneous injection. Best administered fasted to maximize fat-burning effects. Can be taken as a pre-mixed blend or separate injections. Cycles typically run 8-16 weeks. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Mild injection site reactions, headache, nausea. Generally well-tolerated as AOD-9604 lacks many HGH side effects. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |
What They Have in Common
Both AOD-9604 & CJC-1295 & Ipamorelin and Cagrilintide are commonly used for: